Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Choroidal Neovascularization Secondary to Pathologic Myopia”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Large-scale testing (Phase 3)Study completedNCT02034006
What this trial is testing

The Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.

Who this might be right for
Choroidal Neovascularization Secondary to Pathologic Myopia
Novartis Pharmaceuticals 200
Not applicableWithdrawnNCT01218230
What this trial is testing

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

Who this might be right for
Myopic Choroidal Neovascular Membrane
L.V. Prasad Eye Institute
Large-scale testing (Phase 3)Study completedNCT01217944
What this trial is testing

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Who this might be right for
Pathological Myopia
Novartis Pharmaceuticals 277
Testing effectiveness (Phase 2)Study completedNCT01423149
What this trial is testing

Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Who this might be right for
Choroidal NeovascularizationMyopia, Degenerative
Mateon Therapeutics 23
Early research (Phase 1)Study completedNCT00802126
What this trial is testing

Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy

Who this might be right for
Myopia
University of Campania Luigi Vanvitelli 16
Large-scale testing (Phase 3)Active Not RecruitingNCT06176352
What this trial is testing

Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Who this might be right for
Choroidal Neovascularization Secondary to Pathologic Myopia
Hoffmann-La Roche 280
Testing effectiveness (Phase 2)Study completedNCT01037348
What this trial is testing

Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

Who this might be right for
Choroidal Neovascularisation
Novartis 65
Early research (Phase 1)Study completedNCT00407719
What this trial is testing

Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)

Who this might be right for
Choroidal NeovascularizationDegenerative MyopiaPathological Myopia
Johns Hopkins University 10
Not applicableWithdrawnNCT01256580
What this trial is testing

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

Who this might be right for
Choroidal NeovascularizationMyopiaPunctate Inner Choroidopathy (PIC)+5 more
Massachusetts Eye and Ear Infirmary
Large-scale testing (Phase 3)Study completedNCT01922102
What this trial is testing

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Who this might be right for
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Novartis Pharmaceuticals 457
Large-scale testing (Phase 3)Study completedNCT01249664
What this trial is testing

VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)

Who this might be right for
Myopia, Pathological
Bayer 122